“Scleroderma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Scleroderma Market.
The Scleroderma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Scleroderma Pipeline Report:
Companies across the globe are diligently working toward developing novel Scleroderma treatment therapies with a considerable amount of success over the years.
Scleroderma companies working in the treatment market are Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others, are developing therapies for the Scleroderma treatment
Emerging Scleroderma therapies in the different phases of clinical trials are- RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others are expected to have a significant impact on the Scleroderma market in the coming years.
In December 2023, The Scleroderma Research Foundation (SRF), the largest US non-profit funder of scleroderma research, announced that the FDA has approved its Investigational New Drug (IND) application to start the CONQUEST clinical trial and enroll patients. Sanofi and Boehringer Ingelheim, the first pharma partners in this protocol, will each contribute an experimental drug for scleroderma treatment. The trial will evaluate amlitelimab from Sanofi, a monoclonal antibody targeting OX40-Ligand, and BI-1015550 from Boehringer Ingelheim, an oral PDE-4B inhibitor, for safety and efficacy in scleroderma patients with interstitial lung disease (SSc-ILD). Both drugs have shown promise in previous non-scleroderma trials.
In November 2024, Following positive Phase II trial results for scleroderma, Certa Therapeutics plans to initiate a pivotal trial with FT011 in late 2024. The company intends to discuss the trial design and related development plans with the US Food and Drug Administration (FDA) in early 2024, and will also seek complementary scientific advice from the European Medicines Agency (EMA) in mid-2024.
Scleroderma Overview
Scleroderma, also known as systemic sclerosis, is a chronic autoimmune disease characterized by hardening and tightening of the skin and connective tissues. It can affect the skin, blood vessels, muscles, and internal organs.
Get a Free Sample PDF Report to know more about Scleroderma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/scleroderma-pipeline-insight
Emerging Scleroderma Drugs Under Different Phases of Clinical Development Include:
RO7303509: Genentech
AM 1476: AnaMar AB
MK-2225: Acceleron Pharma
BI 685509: Boehringer Ingelheim
Brentuximab: Vedotin Seagen
HZN-825: Horizon Pharmaceuticals
MT-0551: Mitsubishi Tanabe PharmaCorporation
Scleroderma Route of Administration
Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Scleroderma Molecule Type
Scleroderma Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Scleroderma Pipeline Therapeutics Assessment
Scleroderma Assessment by Product Type
Scleroderma By Stage and Product Type
Scleroderma Assessment by Route of Administration
Scleroderma By Stage and Route of Administration
Scleroderma Assessment by Molecule Type
Scleroderma by Stage and Molecule Type
DelveInsight’s Scleroderma Report covers around 50+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Scleroderma product details are provided in the report. Download the Scleroderma pipeline report to learn more about the emerging Scleroderma therapies
Some of the key companies in the Scleroderma Therapeutics Market include:
Key companies developing therapies for Scleroderma are – Boehringer Ingelheim International GmbH, Celgene Corporation, Johnson & Johnson Services, Inc., Prometic Life Sciences Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals, Cytori Therapeutics Inc., Bayer AG, F. Hoffman La Roche Ltd, arGentis Pharmaceuticals LLC, GlaxoSmithKline PLC (GSK), Novartis AG, and others.
Scleroderma Pipeline Analysis:
The Scleroderma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Scleroderma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Scleroderma Treatment.
Scleroderma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Scleroderma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Scleroderma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Scleroderma drugs and therapies
Scleroderma Pipeline Market Drivers
Pharmaceutical and Biotechnology Industries striving on the development of new therapy, increased Awareness among people related to the disease are some of the important factors that are fueling the Scleroderma Market.
Scleroderma Pipeline Market Barriers
However, higher healthcare cost, adverse effects associated with the drugs and other factors are creating obstacles in the Scleroderma Market growth.
Scope of Scleroderma Pipeline Drug Insight
Coverage: Global
Key Scleroderma Companies: Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others
Key Scleroderma Therapies: RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others
Scleroderma Therapeutic Assessment: Scleroderma current marketed and Scleroderma emerging therapies
Scleroderma Market Dynamics: Scleroderma market drivers and Scleroderma market barriers
Request for Sample PDF Report for Scleroderma Pipeline Assessment and clinical trials
Table of Contents
1. Scleroderma Report Introduction
2. Scleroderma Executive Summary
3. Scleroderma Overview
4. Scleroderma- Analytical Perspective In-depth Commercial Assessment
5. Scleroderma Pipeline Therapeutics
6. Scleroderma Late Stage Products (Phase II/III)
7. Scleroderma Mid Stage Products (Phase II)
8. Scleroderma Early Stage Products (Phase I)
9. Scleroderma Preclinical Stage Products
10. Scleroderma Therapeutics Assessment
11. Scleroderma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Scleroderma Key Companies
14. Scleroderma Key Products
15. Scleroderma Unmet Needs
16 . Scleroderma Market Drivers and Barriers
17. Scleroderma Future Perspectives and Conclusion
18. Scleroderma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
